← Back to Search

Other

OKN-007 for Brain Tumor (OKN-007 Trial)

Phase 1
Waitlist Available
Led By James Battiste, MD, PhD
Research Sponsored by Oblato, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug on patients with brain cancer that has come back after standard treatments. The goal is to see if this new drug can help treat their cancer.

Eligible Conditions
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Adverse events per patient
Secondary study objectives
6 month progression-free survival
PK level in participants

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All patientsExperimental Treatment1 Intervention
All participants enrolled in this study

Find a Location

Who is running the clinical trial?

Oblato, Inc.Lead Sponsor
4 Previous Clinical Trials
73 Total Patients Enrolled
James Battiste, MD, PhDPrincipal Investigator• Oklahoma University

Media Library

OKN-007 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT01672463 — Phase 1
Brain Tumor Research Study Groups: All patients
Brain Tumor Clinical Trial 2023: OKN-007 Highlights & Side Effects. Trial Name: NCT01672463 — Phase 1
OKN-007 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01672463 — Phase 1
~2 spots leftby Nov 2025